Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.
ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.
AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care. For more ideas in this area, take a look at 43 healthcare AI stocks. NYSE:ABBV Earnings & Revenue Growth as at Aug...
AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.
Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.
The stock is up just 8% this year and could prove to be an undervalued buy.
Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where the dividend coverage story is quietly getting stronger.
Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names by market cap are still trailing the broader market. That gap between performance and fundamentals is creating a window that income and growth investors rarely see at the mega-cap level.
AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.
IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.
JEPI's fat monthly yield has made it a retiree favorite, but a smaller rival running a completely different options playbook has quietly compounded far more wealth over the same period without sacrificing the monthly income routine investors depend on.
ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.
There is no end in sight for the drugmaker's dividend growth streak.
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Allergan Aesthetics, an AbbVie company, reported that the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat masseter muscle prominence. If cleared, BOTOX Cosmetic would be the first neurotoxin approved in the U.S. for this condition, supported by positive Phase 3 trial data. The filing highlights AbbVie’s push to broaden its aesthetics offerings beyond current BOTOX Cosmetic indications. AbbVie (NYSE:ABBV) is drawing fresh attention to its...
Your portfolio could be paying you quarterly income right now from three companies that have raised their dividends for decades straight, but the next ex-dates are approaching fast and missing them means waiting another quarter to collect.
AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ (upadacitinib) as the first systemic treatment in the EU for non segmental vitiligo. The decision also covers RINVOQ as a systemic option for severe alopecia areata in adults and adolescents. These approvals expand RINVOQ’s labeled uses in Europe and add new indications in dermatology and immunology. For investors following AbbVie, this move adds fresh detail to the story around its immunology franchise. The company...
AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to the Apogee deal weighs on shares.
Revenue of $16.99 billion and adjusted EPS of $3.65 both beat estimates
Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.
AbbVie (ABBV) delivered earnings and revenue surprises of +0.28% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.
AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.
AbbVie still looks like a compelling buy at its all-time high.
AbbVie closed above the 230.47 buy point from a cup-with-handle base on June 23 and has climbed 15% from there. The previous day, the stock jumped more than 6% after AbbVie announced it agreed to acquire Apogee Therapeutics. The $10.9 billion deal would strengthen AbbVie's immunology pipeline.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
